Mevacor (lovastatin) tablets
Company: Merck
Approval Status: Approved March 1999
Treatment for: Cardiology
Areas: Cardiology/Vascular Diseases
General Information
Other Useful Resources
Mevacor has been approved for the primary prevention of coronary heart disease in patients without symptomatic cardiovascular disease who have average to moderately elevated total-C and LDL-C and below average HDL-C.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
